Before 1996
Dr. Ma and his team developed multiple High-Performance Liquid Chromatography (HPLC) methods in UK and Canada.
March 1996
As a founder, Dr. Ma established Canadian Phytopharmaceuticals Corporation (CPC) in British Columbia, Canada. Prior to CPC's establishment, Dr. Ma proposed the ginsenoside content ratio in the ginseng plant. This allowed for future HPLC profile development for Panax species. The results have been recognized as international standards.
Late 1996
Dr. Ma actively promoted the concept of Standardization in botanical medicines.
Fall 1997
Dr. Ma, as a player in pharmaceutical analysis, participated in the ginseng evaluation program closely working with American botanical council.
Early 2001
Dr. Ma collaborated with the Chinese State Drug Administration to organize the first International Conference on the Standardization of Phytopharmaceutical Products in Beijing, China.
2004-05
Good Manufacturing Practice (GMP) required by Health Canada, all manufacturers in Canada must meet the requirements.
Early 2005
Dr. Ma signed the contract with the National Research Council of Canada for the research project on Goldenseal. He and his team focused researching on the analysis of formulated botanical products. He specifically focused on the analysis of multiple chemical constituents.
2006-2008
Dr. Ma and his team started working on the stability testing for Natural Health products which pushed the industry for Natural Health product to a higher level.
2009
Dr. Ma and his team utilized RRLC methods to analyze most popular botanical extracts and finished products such as Rhodiola, Epimedium and different ginseng species.
Late 2010-2015
A series of scientific research papers were published by Dr. Ma and his research team on the formulated botanical products.
2015-2018
Dr. Ma and his team's research work on the analysis of Rhodiola, Reish mushroom, Panax notoginseng, Ginkgo biloba, have been accepted by the United States Pharmacopoeia as monographs and international standards.